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Background: A great number of studies have investigated changes induced by morphine exposure in gene
expression using several experimental models. In this study, we examined gene expression changes during chronic
exposure to morphine during maturation and differentiation of zebrafish CNS.
Results: Microarray analysis showed 254 genes whose expression was identified as different by at least 1.3 fold
change following chronic morphine exposure as compared to controls. Of these, several novel genes (grb2, copb2,
otpb, magi1b, grik-l, bnip4 and sox19b) have been detected for the first time in an experimental animal model
treated with morphine. We have also identified a subset of genes (dao.1, wls, bnip4 and camk1γb) differentially
expressed by chronic morphine exposure whose expression is related to mu opioid receptor gene expression.
Altered expression of copb2, bnip4, sox19b, otpb, dao.1, grik-l and wls is indicative of modified neuronal
development, CNS patterning processes, differentiation and dopaminergic neurotransmission, serotonergic signaling
pathway, and glutamatergic neurotransmission. The deregulation of camk1γb signaling genes suggests an activation
of axonogenesis and dendritogenesis.
Conclusions: Our study identified different functional classes of genes and individual candidates involved in the
mechanisms underlying susceptibility to morphine actions related to CNS development. These results open new
lines to study the treatment of pain and the molecular mechanisms involved in addiction. We also found a set of
zebrafish-specific morphine-induced genes, which may be putative targets in human models for addiction and pain
processes.
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Morphine, the most widely known opioid agent, has
been largely used for pain management. Besides non-
analgesic uses of this drug, including experimental de-
pression treatments as a control for opium addiction,
has been developed [1,2]. Despite these common uses,
morphine produces disruptive negative secondary effects
including sleepiness, drowsiness, blurred vision, con-
stipation, and a decrease in blood pressure and appetite.
With continuous use, morphine produces physical tole-
rance and addiction [1,2]. At present, it is widely known
that there are genetic components in the susceptibility
to addiction [3,4], but the specific genes that are in-
volved in this process are scarcely known.
Opioids modify the expression profile of certain
mRNAs in many tissues, including central nervous sys-
tem (CNS), the main target of drugs of abuse [5]. With
the use of microarray analysis, extensive studies have
been focused on identifying morphine-induced changes
in gene expression [6-19]. Other opioid agonist as oxy-
codone [20] and other drugs of abuse, such as cocaine,
cannabis, methamphetamine, amphetamine, ecstasy, al-
cohol, heroin and nicotine [14,21-25], have also been
studied. Up to now, all microarray studies reporting gene
expression changes in response to morphine have been
conducted in rodents and humans. In particular, these
studies were performed in whole tissues (mainly brain),
distinct components of the nervous system (nucleus ac-
cumbens, striatum, hippocampus, frontal cortex, spinal
cord), or cell cultures (primary and cell lines).
Zebrafish (Danio rerio) has been used in research re-
lated to drugs of abuse, studying the changes of gene ex-
pression produced by nicotine [26], amphetamine [27],
and alcohol [28]. In addition, this teleost exhibits con-
ditioned place preference (CPP), a technique used as
a measure of drug reward or reinforcement [29], as
responses to amphetamine and opiates like morphine
[30-32]. These research works demonstrate the existence
of a conserved drug-responsive ‘reward’ or reinforcement
pathway in this teleost (as in all vertebrates), suggesting
that this species may show adaptive changes and beha-
vioural correlates of addiction after prolonged exposure to
addictive drugs.
Zebrafish has also been used to study human disease-
related pathways [33,34], given this organism displays
many benefits in comparison to other vertebrate animal
models: small size, low cost, rapid development, trans-
parency of the embryos, permeability to drugs, high fe-
cundity, and transient genetic manipulation [35,36]. In
this sense, zebrafish is an important tool to analyze
in vivo the molecular mechanisms related to the neu-
robiology of drug addiction, withdrawal and reward
[31,37-39] that cannot be fully established in other ani-
mals models. In contrast to mammalian embryos thatdevelop in the uterus and are influenced by maternal
biochemical processes, zebrafish embryos develop exter-
nally, avoiding the maternal effect on the embryos. This
is essential when dealing with drug exposure, as the
effects observed in mammalian embryos might be due to
the susceptibility of the mother and not the embryo per
se. The study of the direct effects of morphine in the
embryos will provide a better understanding of the mo-
lecular mechanisms that underlie the physical and neu-
robehavioral defects shown in fetuses and offsprings
after maternal morphine consumption [40,41].
Therefore, we used microarray technology to obtain a
profile of genes that are regulated by chronic morphine
exposure on whole zebrafish embryos at 24 h post-
fertilization (hpf), at the end of the segmentation period,
during which the CNS is being formed and differentiated
[37,42,43]. We have shown that zebrafish has endogenous
opioids and opioid receptors with high homology with
other species [44,45]. The effects of morphine on embryos
are probably mediated by the zebrafish mu opioid receptor
(opioid receptor, mu1; oprm1), which exhibits highest
affinity toward morphine from the known opioid recep-
tors [46], and is the opioid receptor essential to mediate
rewarding properties of most drugs of abuse [47,48]. Our
previous studies indicate that at 24 hpf, the expression of
oprm1 is higher than at other stages of development [49].
Therefore, the use of 24 hpf zebrafish embryos treated
with morphine can provide information on the impli-
cation of the opioid system in the maturation and dif-
ferentiation of CNS compared to any other stages of
development. Our goal in this research was to differentiate
functional classes of genes and individual candidates in-
volved in the endogenous systems underlying suscepti-
bility to morphine actions; hence, our efforts were focused
on elucidating the functional significance of sets of dif-
ferentially expressed genes related in some way to neu-
ronal function and/or CNS development. To verify the
results obtained by microarray, 12 selected genes were an-
alyzed by quantitative reverse transcription real-time PCR
(RT-qPCR). After “silencing” (knocking-down; KD) the
oprm1 gene expression by morpholino oligonucleotide in-
jection, we identified a subset of genes that are regulated
by morphine and are related to oprm1 expression.
Our results show that morphine produces changes in
gene expression in zebrafish embryos as has been ob-
tained in rodents and humans [6-19]. Thus, our data, be-
sides being analyzed independently, was also compared
to previous studies, in an effort to determine which
alterations in gene expression are species-specific (zebra-
fish vs. mammalians) and which may be common to all
species in relation to addiction and pain studies. These
results are important since several morphine-induced
genes detected in zebrafish embryos may be putative tar-
gets in human models for addiction and pain processes.
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Microarrays analysis
To examine the global transcriptional profiles of zebrafish
embryos, RNAs generated from six pools of control zebra-
fish embryos and six pools of zebrafish embryos exposed
to morphine were individually hybridized to Affymetrix
Zebrafish Genome Arrays. A set of gene products corre-
sponding to a total of approximately 14900 probes on the
arrays were confidently detected, based on signal intensity
at a fixed value above background levels. Differentially
expressed genes were identified through the Significance
Analysis of Microarrays (SAM) method. As shown in
Figure 1, we identified a total of 1023 gene expression
changes in the above mentioned comparison (representing
1076 probe sets; Figure 1A-C). Of these, 955 genes were
identified as known genes; 401 genes were significantlyFigure 1 Probe-sets and genes differentially expressed by chronic mo
comparison with total probes on the microarray (A) and detail of identified
genes (known and unknown). (D) Number of known genes and detail of g
genes with a fold change (FC) of at least 1.3. Numbers following the categ
of probe-set/genes, see Additional file 1.up-regulated and 561 down-regulated (Figure 1C-D).
Moreover, as shown in Figure 1D, seven genes regulated,
after chronic exposure to morphine, are represented by
more than one probe set in the zebrafish microarray,
and each of the probe set is differently deregulated (up-
or down-regulated); for example: acireductone dioxy-
genase 1 (adi1; Dr.20538.1.A1, +1.15 fold change (FC) and
Dr.9210.2.S1, −1.23 FC) and selenoprotein X, 1a (sepx1a;
Dr.147.1.A1, +1.43 FC; Dr.24956.1.S1, −1.27 FC; and
Dr.16417.1.A1; −1.46 FC). Therefore, distinct gene expres-
sion changes obtained for each one of the probe sets of
each gene might mean that these genes show alternative
splicing and each one of them has at least two isoforms
that are differently regulated by exposure to morphine.
Finally, we specifically identified 255 genes (representing
265 probe sets) showing differential expression with a FCrphine treatment in zebrafish embryos. Identified probe sets in
probe sets up- and down-regulated (B). (C): Number of identified
enes up-, down- and up-/down-regulated. (E): Number of identified
ory names indicate the number of probe-set or genes. For the full list
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regulated and 134 genes (140 probe sets) were down-
regulated by chronic morphine treatment (Figure 1E; see
complete list of differentially expressed genes in Additional
file 1).
Gene ontology analysis
To enhance biological interpretation of the differentially
expressed genes from our microarray studies, we sought if
any of the biological processes or molecular functions were
over-represented by these genes. Therefore we performed
a function enrichment analyses for the differentially
expressed genes using the functional classification tool
DAVID Bioinformatics resources. A representative selection
of meaningful categories is illustrated in Figure 2 and
Table 1. This analysis shows that some categories are spe-
cifically enriched in either up- or down-regulated genes,
whereas other categories show both types of regulation.
Genes involved in oxidation-reduction processes (Gene
Ontology (GO):0055114), proteolysis (GO:0006508), mono-
saccharide metabolic processes (GO:0005996), macromo-
lecular complex assembly (GO:0065003) and generation of
precursor metabolites and energy (GO:0006091) represent
an important part of both up- and down-regulated genes.
Macromolecule catabolic processes (GO:0009057), DNA
metabolic process (GO:0006259), protein catabolic processFigure 2 Gene ontology analysis of zebrafish embryos gene collectio
Significantly enriched GO terms have a probability lower than 0.01 (P value
up- (in red) and down-regulated (in blue) groups if they are significantly en
indicated as full bars whereas non-significantly enriched terms are displaye
the corresponding GO term. For the full list of represent genes in each cat(GO:0030163), homeostatic process (GO:0042592), protein
complex assembly (GO:0006461), proteasome complex
(GO:0000502), and in general, post-translational modi-
fication, protein turnover, chaperones, mainly include
down-regulated genes. There is an over-representation of
up-regulated transcripts associated with secondary metabo-
lites biosynthesis, transport, and catabolism (for complete
details, see supplementary Additional files 2 and 3).
For our study, the different categories within Gene Ontol-
ogy Biological Process can be classified in other “functional”
categories according to databases and consulted publica-
tions (see Discussion section). As shown in Figure 3, more
than one fourth of differentially expressed genes are re-
lated to signal transduction and other biological processes,
including energy metabolism, transcription, protein mo-
dification and degradation, neuronal function, transport,
development, cell structure and organization, apoptosis,
amino acid and protein metabolism, replication and stress
(see Table 2, and for complete list also see supplementary
Additional file 4). In particular, the genes related to
neuronal function are shown in a hierarchical cluster in
Figure 4 and listed in Table 3. These genes were further
investigated in this study resulting in the following
categories of GO Biological Process (Additional file 4):
regulation of transcription [GO:0045449; as for example,
cAMP responsive element binding protein 3-like 3n. Genes were categorized with the Biological Process domain.
) and include at least three genes. GO terms are shown for both
riched in at least one of them. Significantly enriched GO terms are
d as empty bars. Bars represent the number of genes assigned with
egory, see Additional file 3.
Table 1 Examples of significantly enriched GO annotation for the list of morphine-responsive genes
Enriched GO annotation De‐regulation Up‐regulation Down‐regulation
No. genes P value No. genes P value Genes No. genes P value Genes
Oxidation‐reduction process
(GO:0055114)
52 3.4E + 10 18 0.013 acox1, cyp11a1, cyp26b1,
cyp27a1.4, d2hgdh, gapdhs,
34 3.7E + 10 adh8b, aldh18a1, cp, cyp2aa4, dao.1, dhfr,
dhrs13b, mdh1b, phyhd1, ptgr1, sepx1a
Proteolysis (GO:0006508) 37 0.049 11 ube2d2 27 0.036 f7, rad23b, spcs2, uchl5, vsg1
Macromolecule catabolic
process (GO:0009057)
23 0.003 4 ube2d2 19 4.3E + 12 ctbs. LOC553461, rad23b, uvsg1
Monosaccharide metabolic
process (GO:0005996)
18 6.8E + 08 11 3.8E + 09 aldocb,galk2, gapdhs, gpia 7 0.050 mdh1b, pklr
DNA metabolic process
(GO:0006259)
17 0.080 5 mlf1, mphosph8 12 0.054 orc4, rad23b
Protein catabolic process
(GO:0030163)
16 0.002 16 0.002 LOC553461, rad23b, uchl5, vsg1
Macromolecular complex
assembly (GO:0065003)




15 0.012 9 0.006 aldocb, gapdhs, gpia 6 mdh1b, pklr
Homeostatic process
(GO:0042592)




13 0.005 1 12 1.9E + 12
Protein complex assembly
(GO:0006461)
12 0.005 4 8 0.024 fgg, tubb5
Lipid metabolism 9 0.005 4 0.087 acsl1, acsl5 5 0.072
Response to wounding
(GO:0009611)
9 0.010 3 cxcl12a 6 0.042 f7, fgg
Proteasome complex
(GO:0000502)
8 5.1E + 11 8 5.1E + 11
Blood coagulation
(GO:0007596)
7 7.1E + 11 2 tfpia 5 0.005 f7,fgg
Positive regulation of
apoptosis (GO:0043065)
7 0.010 3 bnip4 4
Striated muscle cell
development (GO:0055002)
6 0.060 3 cxcl12a 3 tnnt2a
Intermediate filament
cytoskeleton (GO:0045111)




















Table 1 Examples of significantly enriched GO annotation for the list of morphine-responsive genes (Continued)
Notch signaling pathway
(GO:0007219)
5 0.072 2 dlc 3 vsg1
ribosomic RNA processing
(GO:0006364)




5 0.044 5 0.044 cyp11a1. cyp26b1. cyp51
protein processing
(GO:0016485)
4 0.036 1 3 spcs2
serine family amino acid
metabolic process
(GO:0009069)
4 0.065 2 gcshb 2 dhfr




















Figure 3 Functional categories and number of genes found to be modified by morphine in each category. (A) Functional categories of
genes found to be associated with the exposure to morphine in zebrafish embryos. Numbers following the category names indicate the number
of genes in the category, and those in parentheses are the corresponding percentages. (B) Number of genes (up-, in blue, and down-regulated,
in red) by functional category. For the full list of genes, see Table 2 and Additional file 4.
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less homeobox protein 5a (dlx5a), c-fos FBJ murine os-
teosarcoma viral oncogene (c-fos), hairy-related 4.2-like
(her4.2), jun B proto-oncogene and b (juna and junb),
neurogenic differentiation factor 6-B (neurod6b), ortho-
pedia b (otpb), SRY-box containing gene 19b (sox19b), and
sox21b], neuron differentiation [GO:0030182; v-erb-b2
erythroblastic leukemia viral oncogene homolog 2
(erbb2), otpb, N-ethylmaleimide-sensitive factor a (nsfa),
delta-like protein C Precursor (dlc)], somitogenesis
(GO:0001756; dlb, dlc, her4.2) and glutamine biosynthetic
process [GO:0006542; solute carrier family 1 (glutamate/
neutral amino acid transporter), member 4 (slc1a4) and
solute carrier family 1 (glial high affinity glutamate trans-
porter), member 3a (slc1a3a)].Validation of microarray data by quantitative reverse
transcription real-time PCR (RT-qPCR)
RT-qPCR analysis was used to confirm a set of gene
expression changes observed in the microarray analysis.
Chosen genes for RT-qPCR confirmation were mainly
selected based on ontological categories with potential
roles in the nervous system.
To choose the most stable genes as internal references
for RT-qPCR data normalization, four candidates [β-actin
(β-act), ribosomal protein L13a (rpl13a), β-2-microglobu-
lin (β2 mg) and elongation factor-1α (ef1α)] were selected
according to their expression levels detected in the micro-
array studied. The expression of these four genes was also
measured by RT-qPCR. The NormFinder software [50]
was used to calculate the intra- and inter-group variations
Table 2 Functional categories and number of genes found to be modified by morphine in each category
Functional
categories
N genes Up‐regulation Down‐regulation
Signal transduction 311 152 ppp1r14ab, camk1γb, grb2, sept9a, itih3,
ahnak, hrc, sesn3, megf6, btr22, tmem101,
magi1b, vldlr*, hspb1*, plg*
159 LOC566752, a2ml, sh3bp5la, fam115, txndc9,
tctex1d2, rcan2, rnf220b, hspb8, slc1a4*, wls*, grik‐l*
Energy metabolism 190 85 itih3, acox1, soat1, cyp17a2, cyp51, cox4.2,
alpp, aldocb, pcmt*, plg*
105 aldh8a1, pklr, mpdu1b, mdh1b, phyhd1, hrasls,
glb1l, glud1b*
Transcription 109 35 dcps, zbtb16, creb3l3*, junb*, dlx5a*, fos*,
dlx4a*
74 sox19b, mettl11a, noc2l, dbx1b, junbb, her4.2, otpb*,




94 31 ube2d2, hspb1*, plg* 63 pcmt, rad23b, fbxo25, hspb8
Transport 90 43 slc31a1, abca12, apoea, abcb5, ctssb.2*,
slc3a2*, abt4*, slc1a3a*, slc7a8*
47 a2ml, bcap31, aqp12, aqp3a, vamp5, slc1a4*, vamp4*,
hiat1b*, apoIV*, brp44*, kctd12.2*
Neuronal function 95 36 bnip4, ppp1r14ab, acox1, serinc5, maptb,
magi1b, hspb1*, plg*, aplp*, slc1a3a*, creb3l3*,
hsp90a.1*, junba*, dlx5a*, fos*, glula
59 pcmt, dao.1, sox19b, a2ml, mettl11a, astn1, noc2l,
copb2, dbx1b, junbb, her4.2, slc1a4*, her3*, wls*,
grik‐like*, otpb*, cyrano*, sox11b*, sr*, sox21b*, glulb*,
glud1b*, dnmt3b*, kctd12.2*, sox11b*, mir429b*
Development 80 36 bnip4, ppp1r14ab, camk1γb, acox1, ahnak,
maptb, zbtb16, cyp11a1, magi1b, hspb1*, plg*,
dlx5a*, dlx4a*
44 sox19b, a2ml, hspb8, noc2l, copb2, dbx1b, her4.2,




56 27 mybpc2b, maptb, col5a1 29 mylz2, krt1‐19d
Apoptosis 42 19 bnip4, hspb1*, bbc3* 23 hspb8, noc2l, bcap31, casp9*, mir429b*
Cell cycle 31 15 sept9a, sesn3, ccnt1, hsp90a.1*, ccnd1* 16 ccnb3*
Immune response 30 12 ccl‐c11b, cxcl12a, ctssb.2*, plg* 18 crfb6
Amino acid and
protein metabolism
28 11 hnmt, eif4a2, eif3hb, eif2c2, slc3a2*, slc7a8* 17 fah, dao.1, aldh18a1, iars, eif4g2b*, sr*, eif4g2a*,
eif2s1l*
Replication 25 5 h1fx 20 rad23b, mettl11a, noc2l, h2afx*, dnmt3b*
Ribosomal 17 7 rpf2 10 nob1, fcf1
Response to
chemical stimulus
9 3 hspb1*, hsp90a.1* 6 hspb8
Translation 8 2 gcn1l1 6 hbs1l*
Blood Coagulation 8 3 serping1 5 fgg
Stress 7 3 sesn3, hspb1*, hsp90a.1* 4 hspb8
Reproduction 4 3 1
Some up-regulated genes with FC > 1.0 and down-regulated genes FC < −1.0 are marked with an asterisk (*).
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most stable gene, whereas rpl13a, β2 mg and ef1α are less
stable (data not shown). Thus, the mean of threshold cycle
(Ct) value and primer efficiency value of β-act was used
for normalization.
As shown in Table 4 and Figure 4, we examined a total
of 12 regulated genes after chronic morphine exposure
on zebrafish embryos (represented by 14 probe sets in
the microarray system studied) using RT-qPCR tech-
nique. The up-regulated genes include: acyl-Coenzyme
A oxidase 1, palmitoyl (acox1), growth factor receptor-
bound protein 2 (grb2), and Ca2+/calmodulin-dependent
protein kinase Iγb (camk1γb). The group of down-
regulated genes is formed by the transcription factor
sox19b (also named sox31) and wntless (wls, also known
as gpr177).It is of interest that the probe set that presents the
highest gene expression (Dr.26538.1.A1; +4.73 FC), puta-
tively identified by Affymetrix as wls, do not aligned to
wls genomic locus. Our in silico analyses demonstrated
that when performing a Blastn in the Ensembl site, using
as query an unique sequence of 59 nucleotides formed
by the overlapping of 16 probes which constitute this
probe set, the query sequence is aligned in two unidenti-
fied non-coding regions (on chromosomes 6 and 8) that
do not belong to wls genomic locus located on chro-
mosome 2. Therefore, Dr.26538.1.A1 probe set cannot
be identified as wls gene (see other genes differentially
expressed by morphine validation by our in silico studies
in Additional file 5). Concerning the wls gene, we have
detected that uniquely the Dr.3546.1.S1 probe set is
complementary to this gene (Table 4).
Figure 4 Hierarchical cluster of probe sets regulated in zebrafish embryos following chronic morphine exposure. Raw data from six
independent hybridizations are presented for the two experimental groups: control and morphine-treated embryos zebrafish. The probe-set selection
was based on a standard statistical analysis with Robust Multi-array Analysis (see Methods for details). Hierarchical cluster analysis was performed using
Cluster 3.0 and Treeview software and the tree image represents low (in blue) or high expression (in red) of probe sets. These probe sets represent 87
genes (representing 93 probe sets) involved in Neuronal Function (a complete list is provided in Additional file 4). The twelve genes (fourteen probe
sets) chosen for validation of microarray data by RT-qPCR are listed (right hand side of the figure).
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phine treatment involved specifically in dopaminergic and
serotonergic neurotransmission. A gene putatively related
to serotonergic neurotransmission is BCL2/adenovirus
E1B interacting protein 4 (bnip4). Three genes involved in
dopaminergic neurotransmission are the plasminogen
(plg), coatomer protein complex subunit beta 2 (copb2),
and the transcription factor otpb. Furthermore, we in-
cluded in our study three genes related to glutamatergic
neurotransmission: one up-regulated (membrane associ-
ated guanylate kinase, WW and PDZ domain containing1b, magi1b) and two down-regulated (D-amino-acid
oxidase 1, dao.1, and a kainate-like receptor, grik-l).
We showed that two regulated genes, after chronic mor-
phine exposure, are represented by more than one probe set
in the zebrafish microarray (bnip4 and grb2; Table 4). Dis-
tinct gene expression changes obtained for each one of the
probe sets for each gene might mean that these genes show
alternative splicing and each one of them has at least two iso-
forms that are differently regulated by exposure to morphine.
All genes chosen for RT-qPCR confirmation and in-
volved in neuronal functions are also related to other
Table 3 Genes involved in neuronal function with −1.30 ≥ R fold ≥ 1.30
Gene symbol Gene description R.fold Probeset ID
UP‐REGULATION
bnip4 BCL2/adenovirus E1B interacting protein 4 2,357 Dr.24320.1.S1_at
ppp1r14ab Protein phosphatase 1, regulatory (inhibitor) subunit 14Ab 2,239 Dr.19567.1.S1_at
camk1γb Calcium/calmodulin‐dependent protein kinase Iγb 2,164 Dr.9852.1.A1_at
acox1 Acyl‐Coenzyme A oxidase 1, palmitoyl 1,741 Dr.3576.1.A1_at
serinc5 Serine incorporator 5 1,480 Dr.7467.1.S1_at
maptb Microtubule‐associated protein tau b 1,462 Dr.16118.1.A1_at
dlc Delta‐like protein C Precursor 1,375 Dr.16183.1.S1_at
dmxl2 Dmx‐like 2 (rabconnectin‐3) 1,367 Dr.12467.1.A1_at
lmbr1l limb region 1 like 1,346 Dr.19947.1.S1_at
fam120c Family with sequence similarity 120C (constitutive coactivator of PPAR‐gamma‐like protein 2) 1,334 Dr.18209.1.A1_at
magi1b Membrane associated guanylate kinase, WW and PDZ domain containing 1b (BAI1‐associated protein 1) 1,300 Dr.4477.1.A1_at
DOWN‐REGULATION
dao.1 D‐amino‐acid oxidase 1 −1,943 Dr.3663.1.A1_at
sox19b SRY‐box containing gene 19b −1,802 Dr.25405.1.A1_at
a2ml Alpha‐2‐macroglobulin protein‐like −1,801 Dr.3025.1.A1_at
astn1 Astrotactin 1 −1,484 Dr.14729.2.A1_at
enc1 Ectodermal‐neural cortex (with BTB‐like domain) −1,466 Dr.9565.1.S1_at
copb2 Coatomer protein complex, subunit beta 2 −1,393 Dr.14687.1.A1_at
mchr1b Concentrating hormone receptor 1b −1,387 Dr.24966.1.S1_at
dbx1b Developing brain homeobox 1b −1,364 Dr.8072.1.S1_at
junbb Jun B proto‐oncogene b −1,356 Dr.737.1.A1_at
her4.2 Hairy‐related 4.2 −1,324 Dr.20386.1.S1_at
lrrn1 Leucine rich repeat neuronal 1 −1,309 Dr.24292.3.A1_a_at
Genes were identified as being differentially regulated (up- and down-regulated) in embryos zebrafish by morphine treatment.
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publications, such as development (acox1, camk1γb,
sox19b, plg, otpb, copb2, wls, bnip4 and magi1b), signal
transduction (camk1γb, grb2, plg, wls, grik-l and magi1b),
transcription (sox19b and otpb), apoptosis (bnip4), energy
metabolism (acox1 and plg) and, specifically, amino acid
and protein metabolism (dao.1) (see details in Table 2). It
should be emphasized that among all genes confirmed by
RT-qPCR some have previously been identified in distinct
studies with mammals, such as Camk1γ, Plg, Dao and Wls
[10,12,15,51,52] (Table 5).
For our RT-qPCR analysis, we used the same RNA sam-
ples as those used for the microarray hybridization experi-
ment, and additionally, samples from eight independent
chronic morphine treatments were also used. Results from
all the RT-qPCR experiments are summarized in Table 4
and Figure 5: acox1, bnip4, camk1γb, magi1b, and grb2
appeared as the most up-regulated transcripts with 2.03 ±
0.43, 1.90 ± 0.41, 1.90 ± 0.57, 1.55 ± 0.12, and 1.27 ± 0.15
FC, respectively. We also clearly confirmed down-
regulation of sox19b, grik-l, dao.1, copb2, wls and otpb
transcripts (−3.31 ± 0.11, −2.94 ± 0.21, −2.09 ± 0.19, −1.69 ±0.19, −1.67 ± 0.16, −1.64 ± 0.23 FC, respectively). However,
the up-regulation of plg was not confirmed by RT-qPCR
since the result showed no significant deregulation. Dif-
ferences between RT-qPCR and microarray experiments
occur for several reasons, including the fact that different
probes are used for the microarray and RT-qPCR experi-
ments (which can capture differential expression in splice
variants), differences in the methods for normalization
of expression data and possible false-positive expression
changes. In addition, lower correlations between RT-
qPCR and microarray results, such as for plg gene (+1.26
FC), were consistently reported for genes exhibiting small
degrees of changes, generally less than 1.4 FC [53].
Correlation between the microarray and RT-qPCR re-
sults for the 12 selected genes was then performed and
the statistical significance of the correlation determined.
As Morey et al. [53] suggest, prior to performing corre-
lation analysis, the dataset should be tested for normality
using the Shapiro-Wilk test; our data points were not nor-
mally distributed and therefore Spearman’s rho test was
used. This test is the rank-based non-parametric equiva-
lent of the more commonly used Pearson’s correlation
Table 4 Comparison between microarray and RT-qPCR












bnip4 2.36/1.23 1.90 ± 0.41* 7.42 E‐05
Dr.9852.1.A1_at camk1γb 2.16 1.90 ± 0.57* 1.41 E‐05
Dr.7717.2.A1_at
Dr.7717.1.A1_at
grb2 2.02/1.58 1.27 ± 0.15* 8.98 E‐04
Dr.3576.1.A1_at acox1 1.74 2.03 ± 0.43* 2.04 E‐05
Dr.4477.1.A1_at magi1b 1.30 1.55 ± 0.12* 5.43 E‐05
Dr.3645.1.S1_at plg 1.26 −1.06 ± 0.21 0.299
Down‐regulation
Dr.3663.1.A1_at dao.1 −1.94 −3.31 ± 0.11* 3.59 E‐08
Dr.25405.1.A1_at sox19b −1.80 −2.09 ± 0.19* 0.001
Dr.14687.1.A1_at copb2 −1.39 −1.69 ± 0.19* 0.004
Dr.3546.1.S1_at wls −1.25 −1.67 ± 0.16* 0.006
Dr.3211.1.A1_at grik‐l −1.23 −2.94 ± 0.21* 2.53 E‐04
Dr.8118.1.A1_at otpb −1.22 −1.64 ± 0.23* 0.004
Values of fold change by RT-qPCR are given as mean of fold change ± standard
deviation. The study includes samples used for microarray hybridization and
samples from independent treatments; a total of n = 8. For better comparison of
the results obtained with both techniques, microarray and RT-qPCR, Morphine vs.
Control fold changes are indicated with positive and negative values for up- and
down-regulations, respectively. A one-way t-test was performed to determine
whether fold changes obtained for morphine-regulated genes were different
from 1 and significant values are indicated with asterisks.
Table 5 Example of genes differentially expressed by morphi
Probeset ID Genename Description/validati
Up‐regul
Dr.9852.1.A1_at camk1γb Calcium/calmodulin‐depende
Dr.23925.1.A1_at soat1 Sterol O‐acyltransferase (acyl‐Coenzyme
Dr.19223.1.S2_at aldocb Aldolase C, fructose‐bis
Dr.11457.1.S1_at zbtb16 Zinc finger and BTB doma
Dr.12489.1.S1_at mlf1 Myeloid leukemia
Dr.18505.1.S1_at ccnt1 Cyclin‐T1
Dr.822.1.S3_at cxcl12a Chemokine (C‐X‐C motif) ligand 12a (
Dr.23722.1.S1_at cyp27a1.4 Cytochrome P450, family 27, subfam
Dr.9423.1.S1_at ndufb2 NADH dehydrogenase (ubiquinone) 1
Dr.867.1.S1_at wdr1 WD repeat dom
Dr.12378.1.S1_at hspb1 Heat shock protein, alpha‐c
Dr.3645.1.S1_at plg Plasminoge
Down‐reg
Dr.3663.1.A1_at dao.1 D‐amino‐acid ox
Dr.9860.1.S1_at mdh1b Malate dehydrogenase 1
Dr.19735.1.S1_at phyhd1 Phytanoyl‐CoA dioxygenase d
Dr.5687.1.A1_at hspb8 Heat shock protein, alpha‐c
Dr.737.1.A1_at junbb Jun B proto‐onco
Dr.3546.1.S1_at wls wntless homolog (D
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tected by microarray and RT-qPCR are plotted in Figure 6.
The RT-qPCR and microarray methods showed excellent
qualitative agreement on both up- and down-regulated
genes. The correlation between microarray and RT-qPCR
data obtained a high statistical significance [r (12) = 0.884,
p < 0.001]. As mentioned before, the expression of several
morphine-induced genes identified in previous studies
(see Table 5), such as camk1γb, dao.1 and wls, was also
analyzed to evaluate the data reliability and the sensitivity
of microarray analysis. As shown in Figure 5, the induced
expression of camk1γb and decreased expression of wls
was successfully detected by both RT-qPCR and micro-
array approaches. These results confirmed the reliability
of microarray analysis method in this study.
The role of oprm1 gene in morphine-induced regulation
of differentially expressed genes in zebrafish embryos
The effects of morphine in the embryos are probably
mediated by oprm1, the opioid receptor that exhibits
highest affinity towards morphine [46]. Thus, in order
to establish the role of oprm1 in the expression of the
identified genes in our study, we microinjected specific
morpholino (MO) to knock-down (KD)-oprm1 at the
one-to-four-cell stage in the yolk (named oprm1-MO
group; Figure 7), embryos were analyzed when the 24
hpf stage was reached.ne in our study and identified in other species
on in silico R.fold Species Reference
ation
nt protein kinase Igb 2,16 Mouse [12]
A: cholesterol acyltransferase) 1 1,69 Rat [16]
phosphate, b 1,49 Rat [105]
in containing 16 1,44 Mouse [12,65]
factor 1 1,44 Mouse [8]
1,44 Mouse [6]
stromal cell‐derived factor 1) 1,38 Mouse [8]
ily A, polypeptide 1, gene 4 1,35 Mouse [8]
beta subcomplex, 2, 8 kDa 1,31 Mouse [6]
ain 1 1,28 Rat [105]
rystallin‐related, 1 1,27 Rat & mouse [16,55]
n 1,26 Rat & mouse [12,15]
ulation
idase 1 −1,94 Rat [51,52]
b, NAD (soluble) −1,79 Rat [105]
omain containing 1 −1,56 Mouse [55]
rystallin‐related, b8 −1,45 Mouse [8,55]
gene b −1,36 Rat & mouse [7]
rosophila) −1,25 Mouse [10]
Figure 6 Validation of microarray data by RT-qPCR. Correlation between microa
rho test and a high statistical significance [r (12) = 0.884, p < 0.001] was observed. Va
is labeled with a symbol and up- and down-regulated genes are marked in red and
x, camk1gb and sox19b; Ӿ, acox1 and wls; +, grik-l; −, plg. In the case of two regulate










































Figure 5 Quantitative real-time PCR (RT-qPCR) was used to validate
the microarray data. The genes selected showed similar expression
changes when assessed by RT-qPCR as determined by microarray
analysis. Data are presented as morphine vs. control fold changes.
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any morphological alteration in the embryos. We found a
decrease of the mRNA expression level approximately 95%
(data not shown) in the oprm1 which was similar to that
was reported by previous studies of our group [54-56].
To establish that changes observed after MO microinjec-
tions were produced by MO action on their target, we also
employed two more experimental groups (see Figure 7):
embryos injected with standard MO (not targeting any
gene in zebrafish, named MO Control group), and em-
bryos with oprm1-MO injection plus exposure to mor-
phine (oprm1-MO+morphine group).
As shown in Figure 7, our results demonstrated that the
gene expression of grb2, acox1, dao.1, wls, grik-l, otpb and
copb2 in the oprm1 morphants group (oprm1-MO) was
decreased with respect to the Control group, indicating
that oprm1 is important in the expression of these genes
(Figure 7A-G). When the oprm1-MO group was exposed
to morphine (oprm1-MO +morphine group), grb2 ex-
pression was recovered and similar values were reached
with respect to Control groups, including MO Controlrray (x-axis) and RT-qPCR (y-axis) data. This correlation was analyzed by Spearman’s
lues used in this graph were taken from results presented in Table 4. Each gene
green, respectively: ♦, grb2 and dao.1; ●,magi1b and copb2;▲, bnip4 and otpb;
d genes (bnip4 and grb2) after chronic morphine exposure that are represented
data: Dr. 24320.1, bnip4+ 2.36 FC (▲), and Dr. 7717.2, grb2, +2.02 FC (♦).
Figure 7 (See legend on next page.)
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Figure 7 Knockdown of μ opioid receptor (oprm1). Expression levels of grb2, acox1, dao.1, wls, grik-l, otpb, copb2, bnip4, camk1gb, sox19b, magi1b and
plg of the Control group, the Morpholine (MO) control, Morpholine oprm1 (oprm1-MO) and oprm1-MO exposure to morphine (oprm1-MO+morphine). The
expression levels were quantified using RT-qPCR analysis and were normalized to β-actin expression. Each bar represents the FC± SD (n= 8). Data were
analyzed by one-way ANOVA and using the Tukey post-hoc test. P values of < 0.05 being considered statistically significant (***p< 0.001; **p< 0.01; *p <0.05).
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pression levels of acox1, grik-l, otpb and copb2 in the
oprm1-MO +morphine group, we observed an increase
of these genes compared to the oprm1-MO group. The
comparison of gene expression levels of these four genes
in the oprm1-MO+morphine group relative to the two
Control groups shows that gene expression levels of grik-l,
otpb and copb2 were comparable to the Control groups
(Figure 7E-G), but in the case of acox1, it showed a signifi-
cant increase as compared to Control groups (Figure 7B).
Furthermore, dao.1 and wls expression did not undergo
any significant change between oprm1-MO+morphine
and oprm1-MO groups (Figure 7C-D).
Unlike the previous group of genes, the absence of
oprm1-mRNAs (oprm1-MO group) increased the expres-
sion of bnip4, camkγ1b and sox19b genes (Figure 7H-J).
Thus, silencing gene transcription oprm1 indicates that it
appears to be important in some way in the expression of
these three genes. When the oprm1-MO group was
exposed to morphine (oprm1-MO+morphine group),
sox19b expression was recovered and similar values were
reached with respect to the Control groups (Figure 7J). In
contrast, camkγ1b and bnip4 expression did not undergo
any significant change between oprm1-MO+morphine
and oprm1-MO groups (Figure 7H-I). Finally, magi1b and
plg expression did not present any significant change
among all experimental groups (Figure 7K-L).
In conclusion, we found that morphine deregulated
(increased or decreased) the expression of grb2, acox1,
grik-l, otpb, copb2 and sox19b through an unknown (not
related to oprm1) mechanism; however, it required the
expression of oprm1 to exert its influence on the expres-
sion of dao.1, wls, bnip4 and camkγ1b. In other words,
these four genes represent a putative collection of genes
whose expression is related to oprm1 expression.
Discussion
Most of the published data addressing addictive drugs
have focused on adults or neonates in mammalian models
[7-19,57,58]; little information has been published con-
cerning embryonic development and addiction (e.g. [59] –
alcohol-; [10] –morphine-). Nevertheless, the use of
morphine by pregnant women, besides affecting them
personally, also affects their fetuses [60]. It is known
that exposure to morphine may have additional conse-
quences in the mammalian newborn, affecting immune
function, neurodevelopment [61] and long term neuro-
behavioral effects in combination with stress [10,62].In the present study, we used zebrafish embryos, since
in this model external development can be observed,
which is advantageous for the study of the actions of drugs
in a specific embryonic stage (see our recent studies with
cocaine: [55,56,63]).
We described four groups of genes regulated by chronic
morphine treatment in zebrafish embryos. Each group
contains both, genes already known to be related to mor-
phine activity, and new genes that have not been related
to morphine until now. We have also described some
genes whose expression is related to oprm1 expression: (i)
Immediate early genes (IEG) and other genes related to
transcription; (ii) genes involved in monoaminergic neuro-
modulation; (iii) genes involved in glutamatergic neuro-
transmission; and (iv) others genes involved in neuronal
function.
Immediate early genes and other genes related to
transcription
Genes previously known are IEGs, such as members of
the fos and jun families, which have important roles in
processes such as brain development, learning and long-
term neuronal plasticity [64]. Rapid and transient induc-
tion of c-Fos and Jun-B has been described in response
to acute morphine administration in different rat brain
regions [7]. Our results showed that a duplicate of junb
was down-regulated (junbb, −1.36 FC) as well as their
ortholog was up-regulated (junba, +1.18 FC). This fact
suggests that both genes have different functions, such
as reported by Postlethwait et al. [65] indicating a sub-
functionalization of a gene can occur after a gene dupli-
cation event. Additionally, c-fos was also up-regulated
(+1.15 FC). Other known genes deregulated by mor-
phine in zebrafish embryos and related to transcription
are the zinc finger and BTB domain containing 16
(zbtb16; +1.44 FC) and the myeloid leukemia factor 1
(mlf1; +1.44 FC). For both genes some similar results
have been reported in various studies. Thus, zbtb16 was
also induced after acute treatment by morphine in mice
[12], and this induction was lower after prolonged adminis-
tration. Furthermore, this gene was found to be positively
related to CPP induced by morphine in mouse [66]. Anghel
et al. [8] showed that the Mlf1 was also up-regulated by
short-term morphine and conversely down-regulated by
long-term morphine in the pituitary gland of mice.
We also detected other genes involved in the regula-
tion of transcription that have not been identified in pre-
vious studies after morphine treatment, for example,
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and her4.2 (−1.32 FC) that were also deregulated by am-
phetamine in zebrafish, like other members of these
gene families (sox9a, her15 and dlx1a) [27]. With respect
to sox19b, a gene that we validated by RT-qPCR, belong-
ing to the family of SoxB1 transcription factors (sox1/2/
3/19a/19b), its expression is restricted to the developing
CNS, and specifically at 24 h of development in zebra-
fish, it is expressed in the dorsal spinal cord, in the hind-
brain, in the tegmentum of the midbrain and in the
telecenphalon [67], acting as an important determinant
during such anterioposterior regionalization process of
the CNS in zebrafish development [68,69]. Therefore, we
can postulate that the down-regulation of sox19b pro-
duced by morphine exposure in zebrafish embryos could
intervene in some way by altering the CNS anteriopos-
terior patterning process.
Genes involved in monoaminergic neuromodulation
It is widely known that alterations of biogenic amines,
neurotransmitters derived by the enzymatic decarboxy-
lation of naturally occurring amino acids (catecholamines,
dopamine and norepinephrine, as well as serotonin and
acetycholine), by drugs of abuse play an important role in
the CNS [70]. In particular, morphine increases dopami-
nergic neurotransmission in the nucleus accumbens via
the activation of dopamine cells in the ventral tegmental
area (VTA), an area that possesses a high density of
OPRMs (and/or delta opioid receptors, OPRDs), which
may mediate reinforcing effects of morphine [71]. This
activation mainly results from the disinhibition of inhibi-
tory GABAergic interneurons in the VTA. In zebrafish,
dopaminergic and serotonergic systems share similarities
with their mammalian counterparts [72,73]. Although
in mammals, dopaminergic neurons have been observed
in the diencephalon, telencephalon and mesencephalon; in
zebrafish, these neurons have only been detected in the
diencephalon and telencephalon [74,75], and appear du-
ring development between 18–22 hpf in zebrafish embryos
[76]. In particular, zebrafish A11-type dopaminergic neu-
rons (homologous to mammals), the major far-projecting
dopaminergic neurons in this teleost, are located in the
ventral diencephalic (hypothalamus) and posterior tuber-
culum and express specifically the transcription factor Otp
[75,77]. We hypothesized that the dopaminergic neu-
rotransmission during development may be altered by
down-regulation of otpb gene. In zebrafish, two paralogous
otpa and otpb genes have been previously reported [78]
and the requirement for otpa and otpb function during
development of the larval diencephalon is partially re-
dundant. Both genes are essential for the development of
specific subsets of diencephalic dopaminergic neurons in
zebrafish and mice, of neuroendocrine cells and of specific
neurons in the hindbrain in zebrafish [79-83]. Recently,Barreto-Valer et al. [63] showed that cocaine also down-
regulates both duplicate otp genes at 24 hpf zebrafish
embryos, and these transcription factors, besides LIM
homeobox transcription factor 1 and 2-beta (lmx1b.1/2),
were important in the expression of tyrosine hydroxy-
lase (th), the enzyme responsible for the biosynthesis of
dopamine, during the 24 and 48 hpf zebrafish em-
bryonic stages [79].
Another new identified gene, involved also in dopamin-
ergic neurotransmission and down-regulated by exposure
to morphine in zebrafish embryos, is copb2. This gene en-
codes the subunit (of 7 subunits) of coatomer complex,
which is implicated in a variety of functions ranging from
signal transduction, vesicular trafficking and transcrip-
tional regulation to cell cycle control and apoptosis [84].
In particular, Copb2 regulates the transport of dopamin-
ergic receptor D1 [85]. Thus, one mechanism by which
drugs of abuse can regulate the function of dopaminergic
receptors is promoting a decrease in the traffic of dopa-
minergic receptors from the cytoplasm to the cell mem-
brane or vice versa [15]. The trafficking process could be
regulated by changes in gene expression of proteins in-
volved in this process, such as Copb2. On the other hand,
Kily et al. [26] detected that copb2 was down-regulated by
treatment of both nicotine and ethanol in zebrafish; these
authors also demonstrated that copb2 is implied in the de-
velopment of the notochord.
Concerning genes involved in the serotonergic signal-
ing pathway that in our study are deregulated by chronic
morphine treatment, we can mention bnip4 (also named
bnip3b), an unknown gene to date in the context of ani-
mals treated with morphine. We validated by RT-qPCR
the results obtained by microarrays analysis and identi-
fied that the expression of this gene is related to oprm1
expression. In zebrafish, three ortholog genes have been
described: bnip3 and bnip4, not induced by hypoxia, and
bnip3a, which is induced by hypoxia and is much closer
to human BNIP3, which is related to cell death/survival
[86]. In addition, it is known that rat Bnip3 gene is dif-
ferentially regulated during development and induces
both apoptosis and autophagy. Besides it is also involved
in other biological processes, such as mitochondrial dy-
namics and intracellular calcium regulation [87]. We can
hypothesize that the increase of bnip4 expression pro-
duced after exposure to morphine may be involved in a
possible induction of apoptosis/autophagy.
It has interestingly been suggested that mammalian
BNIP3 protein can be a candidate for an intrinsic antide-
pressive effect-related factor and an antistress reaction
factor [88,89]. Enhanced Bnip3 expression in NG108-15
cells, which possess the serotonin 2C receptor (5-HT2CR)
mRNA system, was observed after exposure to Hochu-
ekki-to (HET), a (Wakan-yaku) Sino-Japanese traditional
drug with antidepressive effects, as well as after exposure
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mRNA expression is enhanced under stress conditions
[89]. Thus, both studies speculate that Bnip3 mRNA may
be the candidate gene that is controlled by the 5-HT2CR
mRNA system, which plays an important role in the
action of antidepressants together with serotonin trans-
porters and/or noradrenaline transporters, and also may
play a role in the maintenance and/or reformation of
synapses in the brain. Therefore, data published up to
now [86-89] and our own data suggest that antidepres-
sants in mammals and the treatment with morphine in
zebrafish embryos producing an increase in expression
of Bnip3-type genes may initially seem to indicate an
unfavorable pro-apoptotic state of the neuronal cell. In
addition, a second conclusion of functional significance of
bnip4 in zebrafish is that the study of this teleost during
development may be a good model to confirm that bnip4
mRNA is a candidate for one of the genes that are con-
trolled by the 5-HT(2C)R mRNA system. The relation
between morphine and serotonergic neurotransmission is
supported by biochemical studies that demonstrated re-
ciprocal functional interactions of the 5-HT(2A) receptor
and the OPRM1 following activation by morphine [90].
Genes involved in glutamatergic neurotransmission
In addition to monoaminergic neurons, the glutamater-
gic system plays a critical role in drug dependence and
addiction [91]. In relation to this system, we identified
groups of genes that are associated with the modulation
of glutamate signaling, producing neuroplasticity, and
are regulated by chronic morphine treatment, some of
which (as grik-l, slc1a4 and slc1a3a) have not been
described before. Plasticity following chronic drug expos-
ure, including morphine, has been described in the ex-
tended amygdala (formed by nucleus accumbens and
central amygdala) and, in particular, at the interface bet-
ween glutamatergic and monoaminergic systems [58,92].
Within the group of genes down-regulated by expo-
sure to morphine in zebrafish embryos, we found dao.1,
which we have validated by RT-qPCR and identified as a
gene related to oprm1 expression. This gene encodes a
peroxisomal flavoprotein (DAO) that catalyzes the oxi-
dative deamination of neutral and polar D-amino acids
as D-Ser (a co-agonist of N-methyl-D-aspartate (NMDA)
receptor [93]) to hydrogen peroxide, and is expressed in
mammals in the kidneys, liver and almost exclusively
within astrocytes in the spinal cord [94-96]. Unlike our
study, two papers of Yoshikawa et al. [51,52] showed
that acute and chronic treatments with morphine
increases the expression of Dao and serine racemase
(Sr), which catalyzes the direct formation of D-Ser from
L-Ser, in most parts of rat brain, mainly forebrain. In our
study, we detected that both genes were down-regulated
by morphine exposure in zebrafish embryos (in the caseof sr, −1.20 FC). We have found several genes, as for
example dao.1, chemokine (C-X-C motif ) ligand 12a
(cxcl12a), NADH dehydrogenase (ubiquinone) 1 beta
subcomplex 2 (ndufb2), phytanoyl-CoA dioxygenase do-
main containing 1 (phyhd1), and carbonic anhydrase II
(ca2) that were regulated in opposite directions in our
study in contrast to other studies; such differences may
be due to different morphine exposure areas, tissue
(brain) region and/or species.
Interestingly, in rodents, spinal DAO contributes to the
development of central sensitization-mediated chronic
pain and may be a potential target molecule for the treat-
ment of chronic pain and as an efficacious molecule me-
diating morphine tolerance [96,97]. In conclusion, the
decrease of dao.1 expression by treatment with morphine
in zebrafish embryos contrary to that obtained with ro-
dents opens a door hitherto unknown in the use of zebra-
fish as a model to study chronic pain and the effect of
morphine in relation to the dao.1 gene. Future studies will
be required to resolve these unknowns, concerning the
mechanisms of action of this gene in zebrafish.
Other gene involved in serine metabolism, whose
expression was also down-regulated by exposure to
morphine in zebrafish embryos, is the transporter of
neutral amino acids slc1a4 (named also ACT; −1.27 FC).
SLC1A4 seems to be the main uptake system of L-Ser in
neurons [98]. Therefore, the presence of at least three
genes differentially expressed after exposure to morphine
and involved in serine metabolism implies that mor-
phine can alter this type of metabolism influencing mul-
tiple processes involved in this amino acid, such as the
regulation of NMDA receptors [99]. Other genes related
to the primary excitatory amino acid neurotransmitter glu-
tamate, and closely related to signal transduction, whose
expression was altered by morphine treatment in zebrafish
embryos were: a kainate-like receptor (grik-l); the trans-
porter of glutamate slc1a3a (+1.18 FC); glutamate-
ammonia ligases 1a and b (glula: +1.14 FC and glulb: −1.19
FC); and glutamate dehydrogenase 1b (glud1b: −1.18 FC).
In the case of grik-l, we identified by in silico studies that
Dr.3211.1.A1 probe set target sequence is complementary
to deep 3’ untranslation region (UTR) of si:ch211-251b21.1
mRNA, which encodes a protein similar to mammalian
glutamate ionotropic receptors, in particular, a kainate-like
receptor [99]. Furthermore, Xu et al. [100] demonstrated
that si:ch211-251b21.1 as a target gene is regulated by
hedgehog signaling during development, and their ex-
pression was confined to the dorsal neurons of the spinal
cord in wild-type zebrafish embryos at 24 hpf. On the
other hand, it is known that morphine causes alterations
of gene expression in distinct subunits of postsynaptic glu-
tamatergic receptors, including kainate receptors [101].
Therefore, we suggest that the alteration of gene expres-
sion of grik-l by exposure to morphine could modify
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slc1a3a gene, it is known that alteration of the expression
of high-affinity glutamate transporters, like this gene, has
been reported in drug dependence and addiction animal
models [102]. In zebrafish, two orthologs for slc1a3 were
found [103]. slc1a3a was expressed in glia cells of the lar-
val zebrafish brain similar to the expression of mammalian
SLC1A3 (also named GLAST or EAAT1) throughout the
CNS [97,103,104]. SLC1A3 is critical to maintain the
extracellular glutamate concentration in a non-neurotoxic
range [97]. Interestingly, in mammals, it has been reported
that the expression of SLC1A2 mRNA (or GLT1 or
EAAT2), but not SLC1A3, is decreased in the striatum/
nucleus accumbens and thalamus of morphine-dependent
rats [105]. Therefore, we suggest that zebrafish slc1a3a,
whose expression was down-regulated in embryos ex-
posed to morphine, could be the key glutamate trans-
porter in the regulation of the glutamate homeostasis in
this species, and not slc1a3b or slc1a2. Finally, we also
have observed opposite expression for the two orthologs
glul genes, suggesting that both genes have different func-
tions, such as reported Postlethwait et al. [65]. glulb ex-
pression is diminished in the same way as mice Glul is
suppressed by morphine and by other addictive drugs, as
methamphetamine, cocaine and alcohol [106].
Others genes involved in neuronal function
Within the group of genes up-regulated by exposure to
morphine in zebrafish embryos, we found camk1γb, vali-
dated by RT-qPCR and identified as a gene related to
oprm1 expression. This gene is involved in Ca2+ signal
transduction in neuronal development, such as dendrito-
genesis and axonogenesis [107,108]. In particular, CaMKI
contributes strongly to Ca2+-mediated transcription in neu-
rons through crosstalk with the Ras/extracellular-signal-
regulated kinase (Erk) pathway. In cultured hippocampal
neurons or acute slices, NMDA-stimulated activation of
Erk is predominantly mediated through Ca2+/calmodulin-
dependent protein kinase kinase (CaMKK)/CaMKI. Fur-
thermore, this pathway appears to be important for
dendritic arborization where activity-dependent NMDAR
activation of the γ isoform of CaMKI results in MEK/Erk-
mediated CREB regulated transcription of Wnt-2 and
microRNA132 [108]. Therefore, we hipothetize the
overexpression of camk1γb produced by morphine ex-
posure in zebrafish embryos may result in pronounced
acceleration of axon formation, such as reported by
Davare et al. [107].
Another gene down-regulated by exposure to morphine
and identified as a gene related to oprm1 expression is the
wls, a putative orphan G-protein coupled receptor (GPCR)
that encodes a OPRM1 interacting protein, and is con-
served from worms to human [108]. Juul et al. [10] re-
ported that Wls was also down-regulated by treatmentwith morphine in a mouse model of neonatal stress, which
suggests that it can promote the inhibition of Wnt
secretion. Wls is expressed in various brain regions and
peripheral tissues in mammals and during zebrafish em-
bryogenesis suggesting that WLS may play an essential
role in regulating secretion of multiple Wnts throughout
the body and specifically, it might be critical for neuronal
development and morphogenesis among other functions
[109-112]. In particular, zebrafish wls persists at 24 hpf in
the spinal cord and in different areas of midbrain, hind-
brain, midbrain-hindbrain boundary and ventricular zone.
Using antisense morpholinos to KD wls mRNA translation
in developing zebrafish, Jin et al. [110] suggested that wls
expression was required for brain and ear development
during zebrafish embryogenesis. WLS may possibly serve
as a substrate underlying the alterations in neuronal struc-
ture and synaptic organization characteristic of opioid de-
pendence [113]. Regarding these dependence processes, it
should be emphasized that WLS and OPRM1 have been
co-localized in somata and in dendritic processes in the
murine striatum [113,114], and that proteins that interact
directly with the OPRM1, as WLS, influence their biosyn-
thesis, trafficking and signaling [115], suggesting that these
proteins could regulate these types of mechanisms, in-
cluding signaling and trafficking. Reyes et al. [116]
hypothesized that when morphine binds with OPRM1,
the morphine-enhanced interaction between OPRM1 and
WLS causes entrapment of WLS at the cell surface, and
WLS is inefficiently internalized. Subsequently, a larger
proportion of OPRM1 and WLS are present at the plasma
membrane enabling more OPRM1 to be available for
activation by morphine. Thus, inhibiting WLS function in
mediating Wnt secretion is related to a significant
inhibition of Wnt secretion in treatment with morphine.
While WLS is inefficiently internalized after mor-
phine treatment, WLS is efficiently internalized in
the presence of [D-Ala, N-MePhe, Gly(ol)]-enkephalin
(DAMGO) [113,116] as it is known that happens with
morphine. In conclusion, wls down-regulate expression by
treatment with morphine suggesting a decrease down-
stream Wnt signaling, affecting neuronal development
(structure and synaptic organization) and ear development
in particular [109,110,112,113]. Furthermore, we hypo-
thesize that the decrease in wls expression could be a
direct response mediated by the OPRM1. Two reasons
suggest this: (i) our demonstration that wls is a gene re-
lated to OPRM1 expression, and (ii) a direct interaction at
the protein level of WLS and OPRM1. Therefore, both
gene expression and protein levels of wls/WLS are regu-
lating actions of morphine through OPRM1.
Conclusions
We present here detailed changes in transcriptome of a
critical period of zebrafish development, at 24 hpf, a key
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ring chronic treatment of morphine.
Using microarray technology, we identified different
functional classes of genes and individual candidates
(differentially expressed genes) involved in the mecha-
nisms underlying susceptibility to morphine actions re-
lated to CNS development and, in general, the neural
function. In particular, we identified 1023 genes whose
expression is altered after chronic morphine exposure in
zebrafish embryos and, of these, 254 genes had a FC of
at least 1.3.
We found morphine-induced changes in gene expres-
sion that are specific for the zebrafish and other genes
that are similar to mammals. Several morphine-induced
genes were exclusively detected in zebrafish embryos,
which may be putative targets to analyze, in human
models, the problems of addiction and pain. In addition,
we demonstrated that some of morphine-induced genes
identified in our study might also be related in some
way with the opioid system, in particular, the oprm1 ex-
pression, which could open new lines for the treatment
of pain and the molecular mechanisms involved in
addiction.
We suggest that some of the genes differentially ex-
pressed after chronic morphine exposure in zebrafish em-
bryos could produce alterations in neuronal development,
in particular, in notochord (in the case of copb2), spinal
cord (grik-l) and other brain regions (wls and dao.1), CNS
patterning processes (sox19b), differentiation and dopa-
minergic neurotransmission (otpb and copb2). Besides a
possible induction of apoptosis and/or autophagy and
alteration of serotonergic signaling pathway by the de-
regulation of bnip4, and activation of processes of axono-
genesis and dendritogenesis (camk1γb) could be present
in our experimental model. Finally, the down-regulation
of dao.1 expression by treatment with morphine in zebra-
fish embryos contrary to that obtained with rodents opens
a door hitherto unknown in the use of zebrafish as a
model to study chronic pain and the effect of morphine in
relation to this gene.
In conclusion, morphine in distinct species can affect
common targets and some of these molecular targets




Adult zebrafish (wild-type AB strain) were raised in a
cycle of 14 h light: 10 h dark at 26°C in a multi-tank sys-
tem at our Fish Facilities at the Institute of Neuroscience
of Castile & Leon, University of Salamanca. Embryos
obtained from natural fertilization were selected at
24 hpf using a Discovery V8 stereomicroscope (Carl
Zeiss, Germany), after which fish were raised at 28.5°Cand maintained in dishes containing sterile E3 medium
(5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl, 0.33 mM
MgSO4) in distilled water. Embryos staged according to
development in hpf according to Kimmel et al. [42].
Ethics statement
All procedures and experimental protocols were carried
out in accordance with the guidelines of the European
Communities Council directive of 24 November 1986 (86/
609/EEC), current Spanish Legislation (RD 1201/2005,
BOE 252/34367-91, 2005), and following the Guide for
the Care and Use of Laboratory animals as adapted and
promulgated by the US National Institute of Health. All
efforts were made to minimize the number of embryos
used and their possible suffering.
All experiments were performed at the Institute of
Neuroscience of University of Salamanca with the ap-
proval of the Animal Care and Ethics Committee of this
Institution.
Microarray study design and drug treatment
Zebrafish embryos were divided into two experimental
groups: control embryos and embryos at 5 hpf (end of
blastula) exposed to 10 nM morphine and collected at
24 hpf, in order to study the chronic effects of the
exposure to drug. Morphine was administered to the
embryos in their water environment, i.e., diluted in E3
embryonic medium. Microarray experiments were per-
formed using six replicates for each condition, which
contained the RNA of approximately one hundred em-
bryos to minimize the influence of potential individual
differences between the animals and technical variation
introduced by tissue preparation. We previously re-
ported that a concentration of 10 nM morphine is the
highest concentration that can be used without a toxic
effect on the embryos, and close to 5% of the morphine
diluted in the E3 medium is detected in the embryo [54].
Morphine was acquired from the Spanish Ministry of
Health.
RNA isolation and microarray hybridization
Total RNA was purified using TRIZOL® (Gibco BRL,
Gaithersburg, MD, USA) following further RNA purifica-
tion using an RNeasy Mini Kit for RNA clean-up (Qiagen
Sicences, Maryland, USA). RNA quantification and quality
was then assessed using Agilent 2100 Bioanalyzer (Agilent
Technologies, Palo Alto, CA, USA), to test the integrity of
the 18S and 28S rRNA bands, and samples with an RNA
integrity number (RIN) > 8.0 were used.
Microarray analysis was performed in the Cancer
Research Center (CIC) of Salamanca according to stan-
dard procedures. Labelling and hybridizations were per-
formed according to protocols from Affymetrix. Briefly,
100–300 ng of total RNA were amplified and labeled
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agents kit (Affymetrix Inc., Santa Clara, CA, USA), and
then hybridized to GeneChip® Zebrafish Genome Array
(Affymetrix). Washing and scanning were performed
using GeneChip System of Affymetrix (GeneChip
Hybridization Oven 640, GeneChip Fluidics Station 450
and GeneChip Scanner 7G).Microarray hybridization data analysis: normalization,
differential gene expression and ontological analysis
The RMA (Robust Multi-array Analysis) algorithm [117]
was used for background correction and normalization of
fluorescent hybridization signals of the microarrays, both
at internal (intra-microarrays) and comparative (inter-
microarrays) levels. This algorithm was selected over
others available (MAS5, (Affymetrix 2001); MBEI, a
model-based algorithm) [118] because it was deemed to
provide the best precision in signal detection to achieve
adequate multiple-chip normalization [119], especially in
cases of low-level gene expression [117,120,121] by produ-
cing efficient quantile normalization of the distribution of
probe intensities from each array in the context of a
complete set of arrays. We used Bioconductor and R as
computational tools (www.bioconductor.org), to apply
RMA to the data set of 12 microarray hybridizations in-
cluding six different biological replicas corresponding to
each of the different experimental groups under study
(Control and Morphine).
After quantitation of expression level of each probe set
in all microarrays analyzed, the SAM algorithm [122]
was used to identify probe sets displaying significant dif-
ferential expression when comparing the treat samples
to it controls. This algorithm performs statistical dis-
crimination analysis using permutations to check the
stability of variables fulfilling the ‘alternative hypothesis’.
The method calculates the type I error, or number of ex-
pected false positives, using the calculation of the False
Discovery Rate (FDR) parameter [123]. In this report,
genes with an FDR of 10% or less were considered
significant.
Further processing included functional analysis and over
representation calculations based on Gene Ontology (GO)
Annotation Tool and publication data of Database for
Annotation, Visualization, and Integrated Discovery was
made with GeneSpring GX 7.3 and DAVID Bioinformatics
Resources 6.7 (http://david.abcc.ncifcrf.gov/) [124].Data access
The data obtained and discussed in this publication have
been deposited in NCBI’s Gene Expression Omnibus
[125] and are accessible through GEO Series accession
number GSE61062 (http://www.ncbi.nlm.nih.gov/geo/
query/acc.cgi?acc = GSE61062).Quantitative reverse transcription real-time PCR (RT-qPCR)
Total RNA (2 μg), primed with oligo-dT, was reverse-
transcribed into cDNA at 37°C for 2 h using the first-strand
cDNA synthesis kit (Promega Corporation, Madison, WI,
USA) in a 20 μl volume, and stored at −20°C until used,
according to manufacturer’s instructions. In all cases, a re-
verse transcriptase negative control was used for testing
genomic DNA contamination.
Quantitative real-time PCR (qPCR) were performed
using the SYBR-Green method with a 2× Master Mix
(Applied Biosystems). Each reaction contained 10 μL of
Master Mix, 0.4 μL of each pair of primers, 3 μL of each
cDNA sample in a different serial cDNA quantity for
each gene, and MilliQ water up to 20 μl. The amplifica-
tion reaction took place in an ABI Prism 7000 detection
system (Applied Biosystems), with the following con-
ditions: 10 min at 95°C followed by 40 cycles of 15 s at
95°C and 1 min at 60°C depending on each pair of
primers. RT-qPCR experiments were performed in re-
plicates of eight and run in triplicate for each gene pro-
duct examined. The list of used primers is provided in
Additional file 6. Zebrafish β-actin was used as house-
keeping gene.
The comparative Ct method was used for presenting
quantitative data [126]. Following the removal of out-
liers, raw fluorescence data were used to determine the
PCR amplification efficiency (E) according to the for-
mula E = [10 (−1/slope) −1] * 100. All amplifications had
an E value of 100 ± 10% the E value close to 100% being an
indicator of efficient amplification. The relative gene ex-
pression value (FC) for each transcript was calculated ac-
cording to the equation 2 −(ΔCt “condition 1” − ΔCt “condition 2”),
where “condition 1” corresponds to experimental samples
(“treatment with morphine”), “condition 2” to samples of
control animals and ΔCt of each “condition” is Ct “experimental
gene” −Ct “endogenous gene” [126]. A standard error for each
relative gene expression value was calculated as a measure
of data variation. Significance from qPCR analysis was de-
termined using a one-way t-test for each gene, testing that
|FC| > 1 is significant (p < 0.05).
Mu opioid receptor morpholino microinjection
Antisense MO oligonucleotides used were provided by
Gene Tools (LLC Philomath, OR, USA). MO injection
was performed according to the methodology developed
by Nasevicius and Ekker [127], for which a microinjection
and micromanipulation system designed especially for the
microinjection of zebrafish embryos was used, coupled to
a stereoscope (Stereo Microscope Discovery V8, Zeiss,
Göttingen, Germany) and a high-resolution camera that
allowed videos and photos to be taken. First, the ideal con-
centration of MO was determined. Accordingly, several
concentrations, looking for small lethal effects and ma-
ximum embryonic survival, were microinjected. Thus, the
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employed; concentrations of 1M were used for oprm1
(MOR-MO group). Moreover, parameters of pressure and
the appropriate time for microinjecting the volume cal-
culated in each pulse (3 nl of solution) were calibrated.
Zebrafish embryo yolks microinjected with MOR-MO and
the MO controls were used in the single-cell stage of
development. Other embryos, in which no solution was
microinjected, were used as a control group. The microin-
jected and the non-microinjected embryos were main-
tained under the same conditions: 28.5°C and in the E3
medium (5 mM NaCl, 0.17 mM KCl, 0.33 mM CaCl2,
0.33 mM MgSO4 in ddH2O). To inhibit oprm1 mRNA
translation we used the following MOR-MO sequence:
AATGTTGCCAGTGTTTTCCATCATG. The efficacy and
specificity of MO employed was demonstrated by Sanchez-
Simon et al. [54].
Additional files
Additional file 1: Table listing the probe-sets of genes expressed
differentially by chronic morphine treatment in zebrafish embryos.
Significance level for each probe-set are presented as d-, p- and q-value.
The expression changes between Morphine vs. Control are showed as R
fold. List of known genes up-, down-, and up-/down-regulated.
Additional file 2: Figure presenting gene ontology analysis of the
zebrafish gene collection. Genes were categorized with the Biological
Process domain. Significantly enriched GO terms have a probability lower
than 0.01 (P value) and include at least three genes. GO terms are shown
if they are significantly enriched in at least one of them. Significantly
enriched GO terms are indicated as black bars whereas non-significantly
enriched terms are displayed as empty bars. Bars represent the number
of genes assigned with the corresponding GO term. For more details, see
also Additional file 3.
Additional file 3: Data file providing the detailed description of
Gene Ontology analysis presented in Figure 2 and Table 1. List of
probe-sets and gene names classified for each GO category.
Additional file 4: Table listing genes differentially expressed by
morphine and included in each functional category presented in
Figure 3 and Table 2. The neuronal function category is emphasized in
two excel sheet tabs (listing genes and Gene Ontology analysis of genes
with neuronal function).
Additional file 5: Table listing genes differentially expressed by
morphine validation by our in silico analysis.
Additional file 6: Table listing the primers used for RT-qPCR.
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